Short-Term and Long-Term Effects of Levetiracetam Monotherapy on Homocysteine Metabolism in Children with Epilepsy: A Prospective Study
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background and Purpose Long-term treatment with some older antiepileptic drugs may lead to hyperhomocysteinemia. Levetiracetam (LEV) is a newer broad-spectrum antiepileptic agent whose effects on homocysteine concentrations remain unclear. The purpose of this study was to prospectively determine the short-term and long-term effects of LEV monotherapy on homocysteine metabolism in children with epilepsy. Methods The study population consisted of 32 children [18 females, 14 males; age 5.94±4.10 years (mean±SD), age range 1–15 years] who received LEV monotherapy for new-onset epilepsy. Serum folate, serum vitamin B12, and plasma total homocysteine (p-tHcy) were measured before and at 2 months (n=32), 6 months (n=25), and 12 months (n=18) of LEV monotherapy. Results p-tHcy was significantly decreased at 2 months of treatment (p=0.031). Furthermore, analysis of covariance showed statistically significant decreases in p-tHcy at 2 months (p=0.013) and 6 months (p=0.015) of LEV treatment after controlling for age, sex, body mass index, and LEV dose. There were no significant alterations in the other parameters during the study. The drug doses were 18.1±7.1, 20.1±9.2, and 21.2±11.8 mg/kg at 2, 6, and 12 months of LEV treatment, respectively. Conclusions In contrast with older antiepileptic drugs, long-term LEV monotherapy in children with epilepsy does not cause adverse alterations on homocysteine metabolism. Larger prospective studies are needed to definitively clarify whether LEV may be considered a safer alternative drug for preventing antiepileptic-drug-induced cardiovascular complications in adult life.
Abstract
Background and Purpose Long-term treatment with some older antiepileptic drugs may lead to hyperhomocysteinemia. Levetiracetam (LEV) is a newer broad-spectrum antiepileptic agent whose effects on homocysteine concentrations remain unclear. The purpose of this study was to prospectively determine the short-term and long-term effects of LEV monotherapy on homocysteine metabolism in children with epilepsy. Methods The study population consisted of 32 children [18 females, 14 males; age 5.94±4.10 years (mean±SD), age range 1–15 years] who received LEV monotherapy for new-onset epilepsy. Serum folate, serum vitamin B12, and plasma total homocysteine (p-tHcy) were measured before and at 2 months (n=32), 6 months (n=25), and 12 months (n=18) of LEV monotherapy. Results p-tHcy was significantly decreased at 2 months of treatment (p=0.031). Furthermore, analysis of covariance showed statistically significant decreases in p-tHcy at 2 months (p=0.013) and 6 months (p=0.015) of LEV treatment after controlling for age, sex, body mass index, and LEV dose. There were no significant alterations in the other parameters during the study. The drug doses were 18.1±7.1, 20.1±9.2, and 21.2±11.8 mg/kg at 2, 6, and 12 months of LEV treatment, respectively. Conclusions In contrast with older antiepileptic drugs, long-term LEV monotherapy in children with epilepsy does not cause adverse alterations on homocysteine metabolism. Larger prospective studies are needed to definitively clarify whether LEV may be considered a safer alternative drug for preventing antiepileptic-drug-induced cardiovascular complications in adult life.
참고문헌 (12)
- Belcastro V, "Antiepileptic drugs, hyperhomocysteinemia and B-vitamins supplementation in patients with epilepsy", Epilepsy Res, 102, pp.1~7 (2012)
- Katsiki N, "The effects of antiepileptic drugs on vascular risk factors : a narrative review", Seizure, 23, pp.677~684 (2014)
- Gorgone G, "Hyperhomocysteinemia in patients with epilepsy : does it play a role in the pathogenesis of brain atrophy? A preliminary report", Epilepsia, 50(Suppl 1), pp.33~36 (2009)
- Baldelli E, "Homocysteine potentiates seizures and cell loss induced by pilocarpine treatment", Neuromolecular Med, 12, pp.248~259 (2010)
- Lyseng-Williamson KA, "Levetiracetam : a review of its use in epilepsy", Drugs, 71, pp.489~514 (2011)
- El-Farahaty RM, "Atherosclerotic effects of long-term old and new antiepileptic drugs monotherapy : a cross-sectional comparative study", J Child Neurol, 30, pp.451~457 (2015)
- Papandreou D, "Reference range of total serum homocysteine level and dietary indexes in healthy Greek schoolchildren aged 6-15 years", Br J Nutr, 96, pp.719~724 (2006)
- Vilaseca MA, "Total homocysteine in pediatric patients", Clin Chem, 43, pp.690~692 (1997)
- Belcastro V, "Hyperhomocysteinemia in epileptic patients on new antiepileptic drugs", Epilepsia, 51, pp.274~279 (2010)
- Kim DW, "Effects of new antiepileptic drugs on circulatory markers for vascular risk in patients with newly diagnosed epilepsy", Epilepsia, 54, pp.e146~e149 (2013)[DOI]
- McKinley MC, "Plasma homocysteine is not subject to seasonal variation", Clin Chem, 47, pp.1430~1436 (2001)
- Patsalos PN, "Pharmacokinetic profile of levetiracetam : toward ideal characteristics", Pharmacol Ther, 85, pp.77~85 (2000)